| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Obinutuzumab |
| Brand | Gazyvaro® |
| Indication | In combination with bendamustine followed by obinutuzumab maintenance for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen. |
| Assessment Process | |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 26/07/2016 |
| NCPE assessment completed | 25/01/2017 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
The HSE has approved reimbursement following confidential price negotiations October 2017.
